Open AccessMBCL-48. OUTCOMES OF TREATMENT BASED ON THE ST. JUDE MEDULLOBLASTOMA-96 REGIMEN FOR JAPANESE CHILDREN WITH MEDULLOBLASTOMA
Author(s) -
Junya Fujimura,
Tomonari Suzuki,
Yuko Watanabe,
Hidetaka Niizuma,
Ryuta Saito,
Masayuki Kanamori,
Yukihiko Sonoda,
Atsuko Watanabe,
Ryuhei Tanaka,
Megumi Fujiwara,
Akinori Yaguchi,
Tatsuro Ishibashi,
Osamu Tomita,
Akihide Kondo,
Toshiaki Shimizu,
Takaaki Yanagisawa,
Teiji Tominaga,
Ryo Nishikawa,
Hajime Arai
Publication year - 2020
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noaa222.518
Subject(s) - medulloblastoma , medicine , regimen , radiation therapy , chemotherapy , chemotherapy regimen , surgery , pediatrics , oncology , pathology
Medulloblastoma is a type of malignant embryonal tumor in childhood that is considered to require multiagent chemotherapy followed by radical resection and craniospinal irradiation (CSI). However, the outcomes of chemotherapy for this tumor in Japan are unclear. Here, we performed a multicenter retrospective study to determine the prognosis of pediatric medulloblastoma patients in Japan treated with the St. Jude medulloblastoma-96 (SJMB96) regimen. Thirty patients with newly diagnosed medulloblastoma received treatment with the SJMB96 regimen at Juntendo University Hospital in Tokyo (n=10), Saitama Medical University International Medical Center in Saitama (n=10), and Tohoku University Hospital in Miyagi (n=10) from 2011 to 2018. All patients underwent tumor resection and CSI, with radiation doses of 23.4Gy for standard-risk patients (n=11) and 39.6Gy for high-risk patients (n=19). Six weeks after radiation therapy, patients received four cycles of high-dose chemotherapy with autologous peripheral blood stem cell transplantation according to the SJMB96 regimen. We found that 5-year overall survival was 80.8% among standard-risk patients and 74.2% among high-risk patients. No treatment-related deaths occurred. Eight patients who experienced recurrence died within 80 months of diagnosis. As these treatment outcomes are comparable to those previously reported outside of Japan, our findings indicate that this regimen is a therapeutic option for medulloblastoma patients in Japan.